<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We originally reported that vitamin K2 (VK2) analogs, including menaquinone 4 (MK4) but not vitamin K1, effectively induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in various types of primary cultured <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells and <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell lines in vitro </plain></SENT>
<SENT sid="1" pm="."><plain>It has also been reported by others that VK2 showed the differentiation-inducing activity in <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell lines </plain></SENT>
<SENT sid="2" pm="."><plain>To investigate the discrepancy between <z:mpath ids='MPATH_3'>apoptosis</z:mpath>- and differentiation-inductions of <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells by VK2 treatment, we used bcl-2 gene transfected <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60 cells (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60-bcl-2) which resulted in five-fold over-expression of BCL-2 protein, and then compared the effects of MK4 to the control <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60-neo cells </plain></SENT>
<SENT sid="3" pm="."><plain>Seventy-two hours of exposure to various concentrations of MK4 resulted in growth inhibition of these cells in a dose-dependent manner (0.1-50 microM), however, <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60-bcl-2 was less sensitive against MK4 </plain></SENT>
<SENT sid="4" pm="."><plain>MK4 potently induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60-neo cells along with the depolarization of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane potential and caspase-3 activation </plain></SENT>
<SENT sid="5" pm="."><plain>Notably, <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60-bcl-2 was almost completely resistant to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induction in response to MK4, although cell growth inhibition was still observed </plain></SENT>
<SENT sid="6" pm="."><plain>In spite of the abrogation of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induction, about 90% of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60-bcl-2 cells were arrested in the G0/G1 phase within 48 h of exposure to 10 microM of MK4 accompanied by up-modulation of p27KIP1 expression </plain></SENT>
<SENT sid="7" pm="."><plain>Concomitantly, <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60-bcl-2 cells underwent monocytic differentiation </plain></SENT>
<SENT sid="8" pm="."><plain>These data suggest that VK2 also shows the differentiation inducing effects on <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells which are resistant against VK2-inducing <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>The dichotomous nature of VK2 against <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells appears to have clinical benefits for the treatment of patients with <z:hpo ids='HP_0001909'>leukemias</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
</text></document>